tiprankstipranks
Trending News
More News >
Irisity AB (SE:IRIS)
:IRIS

Irisity AB (IRIS) AI Stock Analysis

Compare
0 Followers

Top Page

SE:IRIS

Irisity AB

(IRIS)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 5.2)
Rating:48Neutral
Price Target:
kr0.13
▼(-2.31% Downside)
The score is held down primarily by weak financial performance—declining revenue, very large losses, and sustained cash burn—only partially cushioned by low balance-sheet leverage. Technical momentum is a relative positive, but valuation remains challenged due to negative earnings and no indicated dividend yield.
Positive Factors
Recurring subscription model
A subscription licensing model creates recurring revenue and predictable cash flows over time. Combined with indirect channel sales via integrators and partners, this supports scalable distribution, higher customer lifetime value and the potential to grow ARR without linear increases in sales headcount.
Low financial leverage
Very low debt levels reduce fixed financing obligations and give management flexibility to fund operations, endure cash burn, or pursue strategic investments. This balance sheet cushion lengthens runway and lowers bankruptcy risk versus highly levered peers during a multi-quarter recovery.
Strong gross profit
High gross profit relative to revenue indicates software economics and scalability: incremental sales can drop to the bottom line once operating cost growth is controlled. If sales stabilize, margins can expand materially, enabling a clearer path to operating leverage and eventual profitability.
Negative Factors
Declining revenue trend
A multi-period revenue decline undermines operating leverage and complicates achieving profitability. For a software vendor, shrinking top-line reduces ability to spread fixed R&D and sales costs, lengthens payback on customer acquisition, and signals potential product-market fit or distribution execution issues.
Sustained negative cash flow
Chronic negative operating and free cash flow forces reliance on external financing or equity dilution to fund operations. Over months this erodes shareholder equity, limits reinvestment capacity, and constrains strategic options, particularly if revenue recovery is slow or capital markets tighten.
Large losses eroding equity
Losses several times revenue and very negative ROE indicate capital erosion and weak profitability dynamics. Persistent heavy losses reduce book equity, heighten dilution risk, and weaken investor confidence, making it harder to fund growth initiatives or sustain competitive product investment over the medium term.

Irisity AB (IRIS) vs. iShares MSCI Sweden ETF (EWD)

Irisity AB Business Overview & Revenue Model

Company DescriptionIrisity AB (publ) provides AI-powered video analytics solutions in Sweden and internationally. It offers IRIS, a Security as a Service for AI video analytics. The company's software upgrades security cameras to intelligent detection devices and safeguards personal privacy. It provides solutions in the areas of alarm central, critical infrastructure, rail and transportation, education and public, construction, safe and smart city, health and elder care, logistics and ports, industrial, and agriculture. The company was formerly known as Mindmancer AB (publ) and changed its name to Irisity AB (publ) in August 2017. Irisity AB (publ) was incorporated in 2006 and is headquartered in Gothenburg, Sweden.
How the Company Makes MoneyIrisity AB generates revenue through a subscription-based model for its software services, which allows customers to access and utilize its AI video analytics solutions. This recurring revenue stream is a key component of its business model. Additionally, the company earns money from the sale of licenses for its software products and from hardware sales, such as cameras and other security equipment that are integrated with its software. Significant partnerships with security service providers and integrators enhance its market reach, while ongoing technological advancements and a growing demand for smart surveillance solutions contribute to its revenue growth.

Irisity AB Financial Statement Overview

Summary
Income statement and cash flow are very weak: TTM revenue fell (-5.2%), losses are extremely large relative to revenue, and operating/free cash flow are negative. The balance sheet is a partial offset with low leverage (debt-to-equity ~0.12), but equity is being eroded by sharply negative returns (ROE ~-45%).
Income Statement
18
Very Negative
TTM (Trailing-Twelve-Months) revenue declined (-5.2%) and profitability remains deeply negative, with net losses of roughly 3x revenue and negative operating profitability. While reported gross profit is strong relative to revenue, operating costs continue to overwhelm the top line, and losses have generally widened versus earlier years (2023–2024 to TTM), signaling weak operating leverage and an uncertain path to breakeven.
Balance Sheet
54
Neutral
Leverage is low (TTM debt-to-equity ~0.12), and equity remains sizable relative to the balance sheet, which provides some financial flexibility. However, returns on equity are sharply negative (TTM ~-45%), and equity has trended down from prior annual periods—consistent with ongoing losses eroding the capital base over time.
Cash Flow
22
Negative
Cash generation is weak: operating cash flow is negative in TTM and across all annual periods shown, and free cash flow is also negative (TTM and 2024), indicating the business is consuming cash rather than funding itself. There is some improvement versus 2024 in TTM free cash burn, but the overall pattern remains sustained cash outflows and reliance on external funding over time.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue74.15M103.94M117.60M87.68M77.29M36.77M
Gross Profit76.07M106.59M129.13M94.79M70.97M32.00M
EBITDA-101.50M-92.48M-89.84M-94.64M-10.94M-11.49M
Net Income-221.60M-216.07M-132.53M-136.93M-23.93M-19.61M
Balance Sheet
Total Assets528.78M738.23M760.19M863.39M898.89M137.87M
Cash, Cash Equivalents and Short-Term Investments1.59M7.55M13.64M17.58M71.34M65.15M
Total Debt46.95M12.65M23.28M15.00M1.17M2.34M
Total Liabilities131.05M117.20M128.54M124.31M136.85M20.11M
Stockholders Equity397.73M621.02M631.65M739.07M762.04M117.76M
Cash Flow
Free Cash Flow-29.77M-59.87M-69.65M-68.28M-43.25M-21.18M
Operating Cash Flow-55.61M-59.87M-42.71M-41.96M-27.44M-11.14M
Investing Cash Flow-23.14M-33.96M-26.94M-26.33M-90.16M-10.04M
Financing Cash Flow77.46M87.75M63.16M13.77M123.79M46.53M

Irisity AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.13
Price Trends
50DMA
0.14
Negative
100DMA
0.14
Negative
200DMA
0.20
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
44.61
Neutral
STOCH
40.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRIS, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.14, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.61 is Neutral, neither overbought nor oversold. The STOCH value of 40.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IRIS.

Irisity AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
kr88.72B17.3413.13%3.10%-0.74%6.55%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
56
Neutral
kr158.48M-54.24-1.58%2.70%85.94%
56
Neutral
kr471.93M14.901.30%-2.54%
48
Neutral
kr44.95M-0.08-44.40%-41.32%34.95%
47
Neutral
kr153.98M-7.92-10.30%-3.27%-23.22%
41
Neutral
kr111.13M-2.029.39%-378.80%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:IRIS
Irisity AB
0.13
-0.33
-72.47%
SE:PREC
Precise Biometrics AB
2.04
-1.81
-47.06%
SE:SECU.B
Securitas AB
157.45
8.19
5.49%
SE:LEVEL
Nordic LEVEL Group AB Class B
0.65
-0.05
-6.76%
SE:TSEC
Tempest Security AB
10.75
0.83
8.37%
SE:CARE
Careium AB
20.90
-14.00
-40.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 13, 2026